[8-K] Zura Bio Ltd Reports Material Event

Rhea-AI Filing Summary

Zura Bio Limited furnished a press release announcing its third quarter 2025 financial results. The release was provided as Exhibit 99.1 to a Form 8-K dated November 13, 2025. Under Item 2.02, the information (including Exhibit 99.1) is deemed furnished, not filed, and is not incorporated by reference except as specifically stated.

false 0001855644 0001855644 2025-11-13 2025-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

Warrants [Member]

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

November 13, 2025

Date of Report (Date of earliest event reported)

Zura Bio Limited

(Exact name of registrant as specified in its charter)

Cayman Islands		001-40598		98-1725736
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

1489 W. Warm Springs Rd. #110

Henderson, NV 89014

 (Address of principal executive offices,
including zip code)

(702) 825-9872

 (Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Class A Ordinary Shares, par value $0.0001 per share		ZURA		The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, Zura Bio Limited (the “Company”) issued a press release announcing its third quarter 2025 financial results. A copy of the press release is furnished herewith as Exhibit 99.1 and incorporated herein by reference.

The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information in this Item 2.02 (including Exhibit 99.1) shall not be deemed incorporated by reference into any other filing with Securities and Exchange Commission (the “SEC”) made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.		Description
99.1		Press Release dated November 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ZURA BIO LIMITED
Date: November 13, 2025	By:	/s/ Kim Davis
		Kim Davis
		Interim Chief Executive Officer, Chief Operating Officer, Chief Legal Officer and Corporate Secretary

FAQ

What did Zura Bio (ZURA) announce in this 8-K?

The company furnished a press release announcing its third quarter 2025 financial results.

Where can I find the details of ZURA’s Q3 2025 results?

Details are in the press release filed as Exhibit 99.1 to the Form 8-K.

Is the Q3 2025 press release considered filed with the SEC?

No. The information in Item 2.02, including Exhibit 99.1, is deemed furnished, not filed.

What is the date of Zura Bio’s Q3 2025 results announcement?

November 13, 2025.

Which SEC form did Zura Bio use for this disclosure?

Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

What exchange lists Zura Bio’s shares and under what symbol?

The Nasdaq Stock Market under the symbol ZURA.